Cancers, Free Full-Text
Por um escritor misterioso
Descrição
After forty years of essentially unchanged treatment in acute myeloid leukemia (AML), innovation over the past five years has been rapid, with nine drug approvals from 2016 to 2021. Increased understanding of the molecular changes and genetic ontology of disease have led to targeting mutations in isocitrate dehydrogenase, FMS-like tyrosine kinase 3 (FLT3), B-cell lymphoma 2 and hedgehog pathways. Yet outcomes remain variable; especially in defined molecular and genetic subgroups such as NPM1 (Nucleophosmin 1) mutations, 11q23/KMT2A rearranged and TP53 mutations. Emerging therapies seek to address these unmet needs, and all three of these subgroups have promising new therapeutic approaches. Here, we will discuss the normal biological roles of menin in acute leukemia, notably in KMT2A translocations and NPM1 mutation, as well as current drug development. We will also explore how CD47 inhibition may move immunotherapy into front-line settings and unlock new treatment strategies in TP53 mutated disease. We will then consider how these new therapeutic advances may change the management of AML overall.
Information and Resources about for Cancer: Breast, Colon, Lung, Prostate, Skin
Cancers, Free Full-Text
8 Ways to prevent cancer & be healthy -Siteman Cancer Center
Cancers, Free Full-Text
Cancers, Free Full-Text
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
ROS in cancer therapy: the bright side of the moon
Cancers, Free Full-Text
Precision cancer medicine: Concepts, current practice, and future developments - Edsjö - 2023 - Journal of Internal Medicine - Wiley Online Library
Concordance among Gene-Expression–Based Predictors for Breast Cancer
Hypercalcemia and treated breast cancers: The diagnostic dilemma – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on CyberLeninka open science hub.
de
por adulto (o preço varia de acordo com o tamanho do grupo)
